EGFR and adenocarcinoma: Adenocarcinoma was strongly associated with Exon 19 deletion mutation in EGFR-positive patients, consistent with an Indian study finding EGFR mutations in 32% of NSCLC cases, mostly Exon 19 deletions [28].